Incretin Biology and Therapeutics: Transforming Obesity and Associated Diseases (L8)
March 21-24, 2027
| Fairmont Banff Springs, Banff, AB, Canada
Zach Gerhart-Hines, Richard D DiMarchi and Fiona M. Gribble
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
| 8:00–9:30 AM |
Welcome and Keynote Session (Joint) |
|
| |
Daniel J. Drucker †, Lunenfeld-Tanenbaum Research Institute
Incretin Overview; MoA to Weight Control and Benefits to Other Common Associated Diseases |
|
| |
Philipp E. Scherer †, University of Texas Southwestern Medical Center
Role of Adipose Tissue in Incretin-Based Therapeutics |
|
| 9:30–9:50 AM |
Coffee Break |
|
| 9:30–11:15 AM |
Incretins and Adipose Tissue Biology (Joint) |
|
| |
Jeffrey M. Friedman †, Rockefeller University
Integration of Hedonic and Homeostatic Weight Control |
|
| |
Samuel Klein †, Washington University School of Medicine
Metabolic Adaptation after Pharmacological Weight Loss |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 11:15–12:15 PM |
Meet the Editors (Joint) |
|
| 12:15–1:00 PM |
Poster Setup |
|
| 12:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: New Advances in Incretins or Novel MoAs with Therapeutic Potential |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Peripheral versus Central Incretin Action on Homeostasis |
|
| |
Timo D Müller †, Helmholtz Munich
GIP Agonism in the Brain and Periphery |
|
| |
Murielle M Véniant-Ellison †, Amgen Inc.
GIP Antagonism as a Therapeutic Approach |
|
| |
Ryan J. Watts †, Denali Therapeutics Inc
Deep Brain Action of Incretin Agonists: Potential Opportunities and Risks |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 AM |
Emerging Insights into Adipose Tissue and Incretin Pharmacology (Joint) |
|
| |
Ruth E. Gimeno †, Eli Lilly and Company
Incretin Therapies for Combating Neurodegeneration and Addiction |
|
| |
Matthias Blüher †, University of Leipzig
Novel Horizons for Liver and Kidney Health: Translating Incretin Research into Organ-Specific Therapies |
|
| |
Silvia Corvera †, University of Massachusetts Medical School
Therapeutic Targeting of Adipose Depots |
|
| |
Tore Bengtsson †, Stockholm University
sing Highly Selective β2-Agonists for the Treatment of Obesity, Diabetes and Age-Related Muscle Loss |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–12:00 PM |
Panel Discussion: The Future of Incretin Therapeutics: Scientific Impact, Clinical Challenge (Joint) |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Gut-Brain Signaling in Food Preference, Satiety, and Behavior |
|
| |
Fiona M. Gribble, University of Cambridge
Endocrine Signaling in the Gut-Brain Axis |
|
| |
Lora K. Heisler †, Rowett Institute, University of Aberdeen
Uncovering Nonaversive Brain Circuits that Control Feeding |
|
| |
Henning Fenselau †, University of Cologne
Homeostatic Feeding Circuits |
|
| |
Amber L. Alhadeff †, Monell Chemical Senses Center
Neural Circuits Regulating Food Intake and Motivation |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, March 24, 2027
| 8:00–11:00 AM |
Beyond Incretins - Newer Players |
|
| |
Richard D DiMarchi, Indiana University
Chemistry to Enable Greater Efficacy, Safety, and Convenience |
|
| |
Paul M. Titchenell †, Eli Lilly
Clinical Development of Targets for Lean Mass Preservation |
|
| |
Kirsten Raun †, Novo Nordisk A/S
Amylin Mono- and Polyagonists for Metabolic Diseases |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
Beyond Incretins – Unmet Therapeutic Needs |
|
| |
Zach Gerhart-Hines, University of Copenhagen
Energy Expenditure Targets |
|
| |
Manu Chakravarthy †, Roche
Small Molecule Agonists/Biased Agonism |
|
| |
Ania Jastreboff †, Yale University
Clinical Perspective of Unmet Needs |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
